SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001558370-22-017027
Filing Date
2022-11-09
Accepted
2022-11-09 08:11:17
Documents
78
Period of Report
2022-09-30

Document Format Files

Seq Description Document Type Size
1 10-Q clvs-20220930x10q.htm   iXBRL 10-Q 2587863
2 EX-31.1 clvs-20220930xex31d1.htm EX-31.1 15514
3 EX-31.2 clvs-20220930xex31d2.htm EX-31.2 15709
4 EX-32.1 clvs-20220930xex32d1.htm EX-32.1 6407
5 EX-32.2 clvs-20220930xex32d2.htm EX-32.2 6481
  Complete submission text file 0001558370-22-017027.txt   10177135

Data Files

Seq Description Document Type Size
6 EX-101.SCH clvs-20220930.xsd EX-101.SCH 58859
7 EX-101.CAL clvs-20220930_cal.xml EX-101.CAL 66197
8 EX-101.DEF clvs-20220930_def.xml EX-101.DEF 189305
9 EX-101.LAB clvs-20220930_lab.xml EX-101.LAB 517181
10 EX-101.PRE clvs-20220930_pre.xml EX-101.PRE 358666
72 EXTRACTED XBRL INSTANCE DOCUMENT clvs-20220930x10q_htm.xml XML 2226316
Mailing Address 5500 FLATIRON PARKWAY SUITE 100 BOULDER CO 80301
Business Address 5500 FLATIRON PARKWAY SUITE 100 BOULDER CO 80301 (303) 625-5000
Clovis Oncology, Inc. (Filer) CIK: 0001466301 (see all company filings)

IRS No.: 900475355 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-35347 | Film No.: 221370748
SIC: 2834 Pharmaceutical Preparations